Extracorporeal blood purification for acute pancreatitis

Objective. To assess the feasibility of extracorporeal blood purification (EBP) for acute pancreatitis. Material and methods. A retrospective study enrolled 128 patients with moderate-to-severe pancreatitis in 2020—2024. Of these, 53 ones underwent EBP. Clinical outcomes and laboratory parameters were assessed. Results. Early effect of EBP was short-term, and long-term dynamics of laboratory parameters did not demonstrate the advantages of this method. The negative effects of extracorporeal treatment included adverse effects on hemostasis system, serum albumin and hemoglobin. With the same baseline severity of organ dysfunction, EBP showed more severe progression and delayed regression of symptoms. Severe dysfunction (SOFA score > 5) was more common by 10%. After 5-6 days, SOFA score was 1.67±0.31 vs. 0.70±0.10 (95% CI 0.45—1.48, P<0.001). Maximum severity of multiple organ failure was higher by 0.75±0.32 points in case of EBP (95% CI 0.12—1.39, P<0.028). Conclusion. Routine EBP for extrarenal indications is not advisable in moderate-to-severe acute pancreatitis.